Livewire
  • Latest
  • Trending
  • Contributors

Editor's Picks

Editor's Picks

1. Packaging up the Smartgroup result
2. 5 alternative investment options to consider
3. Altium: Exceeded consensus forecasts again
4. Bullet-proofing your equity income portfolio
5. Six high conviction stocks in February

Executive Series - Bionomics Ltd (BNO) CEO & MD, Dr Deborah Rathjen

CommSec
CommSec View the contributor's profile page
Online Stockbroker

CommSec’s Tom Piotrowski speaks with Bionomics Ltd (BNO) CEO & MD, Dr Deborah Rathjen about the company’s newly signed deals with Merck, its new anxiety drug trial and its cancer treatment trials To view more Executive Series interviews, visit: (VIEW LINK)


bno Executive Series Bionomics

Comments

Please sign in to comment on this wire.

TRENDING ON LIVEWIRE

  • Altium: Exceeded consensus forecasts again

    Ben Clark TMS Capital
  • A market anomaly in a high yielding stock

    Tim Hannon Newgate Capital Partners
  • Australia following Britain's GFC playbook

    Livewire Exclusive Livewire
  • FINALLY Australia gets interesting

    Brett Gillespie Ellerston Capital
  • Deep value on offer in quality resource juniors

    Michael Frazis Frazis Capital Partners

View all